Influence of Nevirapine on HCV Viral Load
NCT01277627 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2011-01-17
Summary
Nevirapine-based antiretroviral therapy is associated with lower plasma HCV viral load in HIV/HCV-coinfected individuals.
Conditions
- HCV Infection.
- HCV Viral Load.
Interventions
- DRUG
-
Nevirapine
nevirapine: 400 mg a day.
- DRUG
-
efavirenz, protease inhibitors
efavirenz: 600 mg a day
Sponsors & Collaborators
- collaborator INDUSTRY
-
Valme University Hospital
lead OTHER
Study Design
- Allocation
- NON_RANDOMIZED
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-01-31
- Primary Completion
- 2012-07-31
Countries
- Spain
Study Locations
More Related Trials
-
Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C
NCT00718172 ·Status: COMPLETED ·Phase: PHASE1
-
Impact of Antiviral Therapy on Gastroesophageal Varices.
NCT02758509 ·Status: COMPLETED
-
Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV
NCT00545558 ·Status: COMPLETED ·Phase: PHASE1
-
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
NCT01732796 ·Status: COMPLETED ·Phase: PHASE3
-
Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infected Patients
NCT02176525 ·Status: COMPLETED ·Phase: PHASE1
-
Low Dose Peginterferon-α 2a for Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected Patients
NCT00553930 ·Status: COMPLETED ·Phase: PHASE4
-
Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection
NCT01132313 ·Status: COMPLETED ·Phase: PHASE2
-
Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED)
NCT00724373 ·Status: COMPLETED
-
Factors Associated to Success of Hepatitis C Therapy
NCT00514111 ·Status: COMPLETED
-
Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3
NCT00056862 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia
NCT02825212 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced
NCT00793793 ·Status: COMPLETED ·Phase: PHASE1
-
High Dose Versus Standard Dose of Ribavirin in Patients With Chronic Hepatitis C, Genotype 3
NCT00830609 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults
NCT00100581 ·Status: COMPLETED ·Phase: NA
-
Study Evaluating the Safety of HCV-796 in Subjects With Liver Disease and in Healthy Adults
NCT00314054 ·Status: COMPLETED ·Phase: PHASE1
-
A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV
NCT01949168 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive
NCT00093093 ·Status: COMPLETED ·Phase: PHASE3
-
Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C
NCT01859962 ·Status: COMPLETED ·Phase: PHASE2
-
Impact of HCV Treatment on Neurocognitive Functions and Brain Metabolism
NCT02292966 ·Status: WITHDRAWN ·Phase: PHASE4
-
Evaluating the Safety of ITX 5061 in Treatment-Naive Hepatitis C (HCV)-Infected Adults
NCT01165359 ·Status: COMPLETED ·Phase: PHASE1
-
Antiviral & Antifibrotic Liver Therapy in HCV + Drinkers and Non-Drinkers
NCT00211848 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
NCT01598090 ·Status: COMPLETED ·Phase: PHASE3
-
Incidence of de Novo Hepatocellular Carcinoma After Antiviral Agents for HCV.
NCT03775798 ·Status: UNKNOWN
-
Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir
NCT03855917 ·Status: RECRUITING ·Phase: PHASE4
-
Analysis of Host Genetic Factors in the Occurrence of Anemia and on the Virological Response to a Peg-interferon/Ribavirin Therapy in HIV-HCV Co-infected Patients
NCT01964742 ·Status: COMPLETED ·Phase: NA